“Adalid’s comprehensive LNP technology set eliminates the need for multi-sourcing.”
Petr Cigler
Chief Scientific Officer
Thanks to our integrated IP portfolio, we can custom-design an LNP system to meet all your specific needs.
Explore this page
Outer shell (stabilizer)
LNP compositions
Helper lipids
Ionizable lipids
Nucleic acid cargo
Modular LNP Architecture
Our ionizable-lipid libraries cover flexible and also conformationally constrained structures across conventional and new topologies, giving us precise control over LNP design for particular payloads and indications
Outer Shell (Stabilizers)
Our libraries of lipid-polymer conjugates span diverse proprietary LNP stabilizers that tune particle properties and enable modular attachment of targeting ligands (e.g., antibodies and alternatives).
Composition & Optimization
Adalid builds LNPs from libraries of ionizable lipids (flexible/constrained), helper lipids/sterols, and click-ready polymer–lipid stabilizers for ligand attachment. Our semi-automated, high-throughput assembly platform delivers data-driven structure–performance maps, rapidly optimizing compositions for specific payloads, routes, and targets.
Solutions Tailored For You: We apply our expertise across the entire drug development pipeline
Compound Design & Synthesis
Adalid leverages structure-based design to generate novel LNP components, specifically focusing on ionizable lipids, lipid-polymer conjugates, and targeting ligands. Our in-house synthesis capabilities enable rapid iteration and optimization.
LNP Formulation & Biophysical Characterization
Using our semi-automated, high-throughput assembly pipeline in a 96-well format, we formulate LNPs with tunable physicochemical properties. Each formulation undergoes rigorous characterization, ensuring batch-to-batch consistency and performance.
In Vitro and In Vivo Testing
LNP candidates are screened in a panel of relevant cell lines (including human primary cells) to evaluate transfection efficiency, cytotoxicity, and biological activity of the payload. We employ quantitative assays, phenotyping (e.g., T cell subsets) and advanced imaging to identify the most promising formulations for further development.
Selected LNP formulations are tested in relevant mouse models to assess biodistribution, pharmacokinetics, and therapeutic efficacy. This stage includes both systemic and localized delivery routes, supported by advanced imaging.
Our technology is backed by extensive intellectual property and published research
13
Granted patents
24
Patent aplications
3
Provisional patent applications in the U.S focusing on new ionizable compounds and new lipid-polymer conjugates enabling outer shell technology
Intellectual property in the area of lipid nanoparticles is often related to technologies used in the successful COVID-19 mRNA vaccines. That success, however, also attracted litigation which weakens some important IP families. The foundation of Adalid technology lies in a strong structural differentiation. At present, Adalid's intellectual property includes two active patent families which are focused on ionizable compounds:
1. patent family - consisting of 18 members including PCT (WO2022063350 (A1))
2. patent family - consisting of 18 members including PCT (WO2023001323 (A1))
Next-generation lipid nanoparticles for gene delivery.
Billing information
Adalid Sciences, s.r.o.
Podbabska 2582/30
160 00, Praha 6
Czech Republic
Reg. No 21691053
VAT No CZ21691053
